Aligos therapeutics announces strategic reprioritization of nash and covid-19 programs and confirms key timelines and extension of cash runway to year-end 2024

– pipeline reprioritization emphasizes nash and covid-19 assets, alg-055009 and alg-097558, plus key ongoing collaborations, including the merck & co. (msd) programs in nash – – overall workforce reduction (attrition and reduction in force) of approximately 25% since beginning of january 2022 –

ALGS Ratings Summary

ALGS Quant Ranking